Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

187 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Limitations of inferences from observational databases in amyotrophic lateral sclerosis: all that glitters is not gold.
Armon C, Guiloff RJ, Bedlack R. Armon C, et al. Amyotroph Lateral Scler Other Motor Neuron Disord. 2002 Sep;3(3):109-12. doi: 10.1080/146608202760834094. Amyotroph Lateral Scler Other Motor Neuron Disord. 2002. PMID: 12495570 Review.
Evidence-based guideline update: intraoperative spinal monitoring with somatosensory and transcranial electrical motor evoked potentials*.
Nuwer MR, Emerson RG, Galloway G, Legatt AD, Lopez J, Minahan R, Yamada T, Goodin DS, Armon C, Chaudhry V, Gronseth GS, Harden CL; American Association of Neuromuscular and Electrodiagnostic Medicine. Nuwer MR, et al. J Clin Neurophysiol. 2012 Feb;29(1):101-8. doi: 10.1097/WNP.0b013e31824a397e. J Clin Neurophysiol. 2012. PMID: 22353994
How can physicians and their patients with ALS decide to use the newly-available treatments to slow disease progression?
Armon C. Armon C. Amyotroph Lateral Scler Other Motor Neuron Disord. 1999 Dec;1(1):3-14. doi: 10.1080/14660829952415945. Amyotroph Lateral Scler Other Motor Neuron Disord. 1999. PMID: 12365066 Review.
Patients and physicians who are trying to decide whether to use these treatments require background information: (a) to place these treatments in the context of other treatments; (b) to understand the outcome measures used; and (c) to understand the significance of the eff …
Patients and physicians who are trying to decide whether to use these treatments require background information: (a) to place these treatmen …
Toward earlier diagnosis of amyotrophic lateral sclerosis: revised criteria. rhCNTF ALS Study Group.
Ross MA, Miller RG, Berchert L, Parry G, Barohn RJ, Armon C, Bryan WW, Petajan J, Stromatt S, Goodpasture J, McGuire D. Ross MA, et al. Neurology. 1998 Mar;50(3):768-72. doi: 10.1212/wnl.50.3.768. Neurology. 1998. PMID: 9521272
Linear estimates of disease progression predict survival in patients with amyotrophic lateral sclerosis.
Armon C, Graves MC, Moses D, Forté DK, Sepulveda L, Darby SM, Smith RA. Armon C, et al. Muscle Nerve. 2000 Jun;23(6):874-82. doi: 10.1002/(sici)1097-4598(200006)23:6<874::aid-mus5>3.0.co;2-u. Muscle Nerve. 2000. PMID: 10842262 Clinical Trial.
Can we eliminate placebo in ALS clinical trials?
Bryan WW, Hoagland RJ, Murphy J, Armon C, Barohn RJ, Goodpasture JC, Miller RG, Parry GJ, Petajan JH, Ross MA, Stromatt SC; rhCNTF ALS Study Group. Bryan WW, et al. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003 Apr;4(1):11-5. doi: 10.1080/14660820310006661. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003. PMID: 12745612 Clinical Trial.
Motor unit number estimate-based rates of progression of ALS predict patient survival.
Armon C, Brandstater ME. Armon C, et al. Muscle Nerve. 1999 Nov;22(11):1571-5. doi: 10.1002/(sici)1097-4598(199911)22:11<1571::aid-mus13>3.0.co;2-0. Muscle Nerve. 1999. PMID: 10514236
187 results
Jump to page
Feedback